首页|中晚期肝癌肝动脉灌注化疗的研究进展

中晚期肝癌肝动脉灌注化疗的研究进展

扫码查看
对于部分无法接受肝癌切除术的中晚期肝癌患者来讲,则需要采取如动脉灌注化疗、门静脉插管灌注化疗等姑息性外科手段治疗来抑制病情进展。如果患者肝功能尚可且无法进行切除,肝动脉灌注化疗(hepatic artery infusion chemotherapy,HAIC)则可成为重要治疗手段,其在使肿瘤缩小、坏死的同时又不会对周围健康细胞造成较大负面影响。随着医疗技术的发展进步,临床出现了越来越多的化疗药物。该选择哪种治疗药物,如何进行优化药物配伍方式来抑制肝癌进展,提升患者生存率及预后,成为临床关注的热点问题。文章在参考相关资料的基础上对中晚期肝癌HAIC展开总结分析,以供参考。
Research Progress on Hepatic Arterial Chemoperfusion Therapy for Advanced Liver Cancer
For some patients with advanced liver cancer who cannot accept liver resection surgery,palliative surgical methods such as arterial infusion chemotherapy and portal vein catheterization chemotherapy infusion are needed to suppress the progression of the disease.If the patient's liver function is still acceptable and cannot be resected,hepatic artery infusion chemotherapy(HAIC)can become an important treatment method,which can shrink and necrotize the tumor without causing significant negative effects on surrounding healthy cells.With the development and progress of medical technology,more and more chemotherapy drugs have emerged in clinical practice.The choice of treatment drugs and how to optimize drug compatibility to suppress liver cancer progression,improve patient survival and prognosis have become hot topics of clinical concern.On the basis of referring to relevant materials,the article summarizes and analyzes the hepatic arterial infusion chemotherapy for middle and advanced stage liver cancer for reference.

advanced liver cancerhepatic arterychemotherapylocal perfusiondrug combinationresearch progress

刘纪明

展开 >

菏泽市中医医院介入导管室,山东 菏泽 274000

中晚期肝癌 肝动脉 化疗 局部灌注 药物组合 研究进展

2024

中国卫生标准管理
《中国卫生标准管理》杂志社

中国卫生标准管理

影响因子:1.374
ISSN:1674-9316
年,卷(期):2024.15(14)